一项随机双盲先导研究:评估静脉铁剂与口服铁剂治疗缺铁性贫血患者不宁腿综合征的疗效、安全性和耐受性
本研究为随机双盲双模拟先导试验,计划纳入70例缺铁性贫血合并不宁腿综合征患者,按1:1随机分配至口服硫酸亚铁或静脉铁剂组,第6周评估临床总体印象改善评分和国际不宁腿综合征研究组评分量表评分变化。因COVID-19疫情期间试验实施困难,30例患者最终周数据缺失,故额外招募30例以维持预设统计分析。静脉铁剂与口服铁剂均与不宁腿综合征症状显著改善相关,两组间无统计学显著差异,两组均未观察到严重不良事件。
要点
- 静脉铁剂与口服铁剂均与缺铁性贫血患者不宁腿综合征症状的显著改善相关。
- 两种铁剂治疗组之间疗效无统计学显著差异。
- 两组均未观察到严重不良事件。
核心结论
- 静脉铁剂与口服铁剂均与缺铁性贫血患者不宁腿综合征症状的显著改善相关,两组间无统计学显著差异,两组均未观察到严重不良事件。
研究设计与样本
- 随机双盲双模拟先导试验,计划纳入70例缺铁性贫血合并不宁腿综合征患者,按1:1随机分配至口服铁剂或静脉铁剂组。
- 因COVID-19疫情期间试验实施困难,30例患者最终周数据缺失,故额外招募30例以维持预设统计分析。
主要发现
- 第6周评估主要结局:临床总体印象改善评分和国际不宁腿综合征研究组评分量表评分较基线的变化。
- 静脉铁剂与口服铁剂均与不宁腿综合征症状的显著改善相关,两组间无统计学显著差异。
- 两组均未观察到严重不良事件。
局限性
- 因COVID-19疫情期间试验实施困难,30例患者最终周数据缺失,故额外招募30例以维持预设统计分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Restless legs syndrome (RLS) is a neurological disorder that can have a profound effect on sleep and quality of life. Idiopathic RLS is associated with brain iron insufficiency despite normal peripheral iron stores. There is, however, a five- to six-fold increase in prevalence of RLS in patients with iron deficiency anemia (IDA). Several open-label trials have demonstrated symptomatic improvement in RLS following treatment of IDA using oral or intravenous iron supplementation. To date, there have been no randomized double-blind controlled trials of intravenous iron compared with oral iron for the treatment of RLS patients with IDA. In the current study, oral ferrous sulfate and ferumoxytol were compared for efficacy and speed of response for treatment of RLS occurring in patients with IDA. The planned recruitment for this study was 70 patients with RLS and IDA, to be randomly assigned 1:1 to oral or intravenous iron, using double-blind, double-dummy procedures. At Week 6, the primary outcomes of Clinical Global Impression-Improvement score and change from baseline in the International Restless Legs Syndrome Study Group rating scale score were assessed. Due to challenges, performing the clinical trial during the COVID-19 pandemic, final-week data were found missing for 30 patients. As a result, in order to maintain the prespecified statistical analysis, an additional 30 patients were recruited. Both IV and oral iron were associated with a marked improvement in RLS symptoms, with no statistically significant difference between treatment groups. No serious adverse events were observed in either treatment group.
引用
- Short V, Allen R, Earley CJ, et al. A randomized double-blind pilot study to evaluate the efficacy, safety, and tolerability of intravenous iron versus oral iron for the treatment of restless legs syndrome in patients with iron deficiency anemia. Am J Hematol. 2024. PMID: 38476079. doi:10.1002/ajh.27290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。